Consumer Watchdog Argues That WARF Stem Cell Patent Is Invalid under § 101

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

Consumer WatchdogLast month, Consumer Watchdog filed its opening brief in an appeal of a Board decision affirming the patentability of U.S. Patent No. 7,029,913, arguing that the claims of the '913 patent are invalid because they cover ineligible subject matter and were anticipated and obvious.  The appeal arises from an inter partes reexamination of the '913 patent that Consumer Watchdog, which describes itself as a not-for-profit public charity dedicated to providing a voice for taxpayers and consumers in special interest-dominated public discourse, government and politics, filed in 2006.  The '913 patent, which is assigned to the Wisconsin Alumni Research Foundation (WARF), has three claims.  According to the Consumer Watchdog brief, independent claim 1 (as amended by WARF during the reexamination) recites:

1. (Amended) A replicating in vitro cell culture of pluripotent human embryonic stem cells derived from a pre-implantation embryo, wherein the stem cells (i) will proliferate in an in vitro culture for over one year in an undifferentiated state without the application of exogenous leukemia inhibitory factor, (ii) maintain a karyotype in which the chromosomes are euploid through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iv) are inhibited from differentiation when cultured on a fibroblast feeder layer.

WARFAfter the Patent Office granted Consumer Watchdog's request for an inter partes reexamination (Control No. 95/000,154), the Examiner determined that the pending claims were allowable, and Consumer Watchdog appealed to the Board.  The Board reversed, designating four news grounds of rejection (one anticipation rejection and three different obviousness rejections), and WARF responded by filing a request to reopen prosecution along with an amendment and a declaration.  The Examiner determined that the claims were patentable over the Board's rejections, and the Board affirmed.  Consumer Watchdog's appeal to the Federal Circuit followed.

In addition to arguing that the '913 patent is invalid as anticipated or obvious in view of the references on which the Board based its new grounds of rejection, Consumer Watchdog also argues that the claims of the '913 patent are invalid under § 101.  In particular, the brief states:

As a threshold matter, the claims of the '913 patent are invalid under 35 U.S.C. § 101 for claiming subject matter that is not patent eligible.  Specifically, the claimed hES [human embryonic stem] cell culture falls within the "product of nature" exception to statutory subject matter.  It is within the Court's discretion to address this issue despite the fact that the Board failed to address it below, and is especially appropriate in light of the recent Supreme Court ruling on Section 101 in Ass'n. for Molecular Pathology v. Myriad Genetics, Inc.. 2013 U.S. LEXIS 4540 (June 13, 2013).

Noting that "[t]he Supreme Court restated [in June] that discovery and isolation of a product that occurs in nature does not render that product patent eligible under Section 101," the brief attempts to draw analogies between its appeal and the Myriad case.  For example, the brief states that "[a]s in AMP, the '913 patent's claims are drawn to neither a method of preparation nor a scientific application of the claimed composition."  The brief also suggests that:

The '913 patent's requirement that the claimed culture of cells be in vitro is analogous to the claim limitation in AMP that the DNA be "isolated."  But here there is not even a chemical change between ES cells in an in vivo embryo and ES cells in an vitro culture as there is between human DNA in vivo and isolated DNA in vitro.

Human Embryonic Stem CellThe brief also notes that "[t]he '913 patent does not in any way distinguish the claimed ES cells from those that exist in nature," adding that "if the claimed ES cells were not the same as natural ES cells, the claimed invention would offer very little benefit for medical research."  As the brief argues, "WARF did not create or alter the properties inherent in stem cells any more than Myriad created or altered the genetic information encoded in the DNA it claimed."

Although "[t]he Board never considered whether the claims to hES cells are patent eligible subject matter," the brief contends that "the Court may still consider whether the claims here are invalid under Section 101 because, 'a court may consider an issue antecedent to . . . and ultimately dispositive of the dispute before it, even an issue the parties fail to identify and brief,'" citing U.S. Nat'l Bank v. Indep. Ins. Agents, 508 U.S. 439, 447 (1993).  With respect to the issue of patent eligibility, the brief states that "[c]onsideration of the 101 question is especially appropriate in light of the fact that the Supreme Court's recent AMP decision came after the Board's decision here."

WARF now has until August 12 to file its opening brief in the appeal.

 

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.